Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. https://doi.org/https://doi.org/10.3322/caac.21660.
World Health Organization. Global Tuberculosis Report 2020. rt 2020. Geneva: World Health Organization; 2020. https://www.who.int/publications/i/item/global-tuberculosis-report-2020.
Falagas ME, Kouranos VD, Athanassa Z, Kopterides P. Tuberculosis and malignancy. QJM. 2010;103(7):461–87. https://doi.org/10.1093/qjmed/hcq068.
Article
PubMed
CAS
Google Scholar
Vento S, Lanzafame M. Tuberculosis and cancer: a complex and dangerous liaison. Lancet Oncol. 2011;12(6):520–2. https://doi.org/10.1016/S1470-2045(11)70105-X.
Article
PubMed
Google Scholar
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7. https://doi.org/10.1038/nature01322.
Article
PubMed
PubMed Central
CAS
Google Scholar
Cheng MP, Abou Chakra CN, Yansouni CP, Cnossen S, Shrier I, Menzies D, et al. Risk of active tuberculosis in patients with cancer: a systematic review and meta-analysis. Clin Infect Dis. 2017;64(5):635–44. https://doi.org/10.1093/cid/ciw838.
Article
PubMed
Google Scholar
Ho JC-M, Leung C-C. Management of co-existent tuberculosis and lung cancer. Lung Cancer. 2018;122:83–7. https://doi.org/10.1016/j.lungcan.2018.05.030.
Article
PubMed
Google Scholar
Hong S, Mok Y, Jeon C, Jee SH, Samet JM. Tuberculosis, smoking and risk for lung cancer incidence and mortality. Int J Cancer. 2016;139(11):2447–55. https://doi.org/10.1002/ijc.30384.
Article
PubMed
CAS
Google Scholar
Zaemes J, Kim C. Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature. Eur J Cancer. 2020;132:168–75. https://doi.org/10.1016/j.ejca.2020.03.015.
Article
PubMed
CAS
Google Scholar
Kim DK, Lee SW, Yoo C-G, Kim YW, Han SK, Shim Y-S, et al. Clinical characteristics and treatment responses of tuberculosis in patients with malignancy receiving anticancer chemotherapy. Chest. 2005;128(4):2218–22. https://doi.org/10.1378/chest.128.4.2218.
Article
PubMed
CAS
Google Scholar
Hirashima T, Nagai T, Shigeoka H, Tamura Y, Yoshida H, Kawahara K, et al. Comparison of the clinical courses and chemotherapy outcomes in metastatic colorectal cancer patients with and without active Mycobacterium tuberculosis or Mycobacterium kansasii infection: a retrospective study. BMC Cancer. 2014;14:770. https://doi.org/10.1186/1471-2407-14-770.
Article
PubMed
PubMed Central
Google Scholar
Chai M, Shi Q. The effect of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active tuberculosis: a retrospective analysis. BMC Cancer. 2020;20(1):1121. https://doi.org/10.1186/s12885-020-07622-6.
Article
PubMed
PubMed Central
CAS
Google Scholar
Ye M-F, Su S, Huang Z-H, Zou J-J, Su D-H, Chen X-H, et al. Efficacy and safety of concurrent anti-tuberculosis treatment and chemotherapy in lung cancer patients with co-existent tuberculosis. Ann Transl Med. 2020;8(18):1143. https://doi.org/10.21037/atm-20-5964.
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35. https://doi.org/10.1056/NEJMoa1504627.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2). https://doi.org/10.3322/caac.21596.
Byeon S, Cho JH, Jung HA, Sun J-M, Lee S-H, Ahn JS, et al. PD-1 inhibitors for non-small cell lung cancer patients with special issues: real-world evidence. Cancer Med. 2020;9(7):2352–62. https://doi.org/10.1002/cam4.2868.
Article
PubMed
PubMed Central
Google Scholar
Langan EA, Graetz V, Allerheiligen J, Zillikens D, Rupp J, Terheyden P. Immune checkpoint inhibitors and tuberculosis: an old disease in a new context. Lancet Oncol. 2020;21(1):e55–65. https://doi.org/10.1016/S1470-2045(19)30674-6.
Article
PubMed
CAS
Google Scholar
Barber DL, Mayer-Barber KD, Feng CG, Sharpe AH, Sher A. CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. J Immunol. 2011;186(3):1598–607. https://doi.org/10.4049/jimmunol.1003304.
Article
PubMed
CAS
Google Scholar
Lázár-Molnár E, Chen B, Sweeney KA, Wang EJ, Liu W, Lin J, et al. Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U S A. 2010;107(30):13402–7. https://doi.org/10.1073/pnas.1007394107.
Article
PubMed
PubMed Central
Google Scholar
National Health and Family Planning Commission. National health industry standard for the classification of tuberculosis: WS 196-2017[S/OL]. 2017, Nov. 9.
Editorial Board of Chinese Journal of Antituberculosis. Expert consensus on a standard of activity judgment of pulmonary tuberculosis and its clinical implementation. Chin J Antituberc. 2020;42(4):301–7. https://doi:10.3969/j.issn.1000-6621.2020.04.001.
Google Scholar
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.
Article
PubMed
CAS
Google Scholar
Zhang S-Y, Fu J-Y, Guo X-Y, Wu D-Z, Zhang T, Li C, et al. Improvement cues of lesion absorption using the adjuvant therapy of traditional Chinese medicine Qinbudan tablet for retreatment pulmonary tuberculosis with standard anti-tuberculosis regimen. Infect Dis Poverty. 2020;9(1):50. https://doi.org/10.1186/s40249-020-00660-z.
Article
PubMed
PubMed Central
CAS
Google Scholar
Chinese Medical Association. Clinical treatment guidelines (TB Volume). Beijing: People’s Medical Publishing House; 2005.
Google Scholar
World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. Geneva: World Health Organization; 2020. https://www.who.int/publications/i/item/9789240001503
Google Scholar
Kim TH, Kim J. A case of toxic hepatic event occurring in combination treatment with nivolumab and anti-tuberculosis in advanced lung cancer. J Thorac Oncol. 2018;13(10, Supplement):S1034. https://doi.org/10.1016/j.jtho.2018.08.1995.
Article
Google Scholar
Takata S, Koh G, Han Y, Yoshida H, Shiroyama T, Takada H, et al. Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents. J Infect Chemother. 2019;25(1):54–8. https://doi.org/10.1016/j.jiac.2018.06.016.
Article
PubMed
Google Scholar
Suliman AM, Bek SA, Elkhatim MS, Husain AA, Mismar AY, Eldean MZS, et al. Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review. Cancer Immunol Immunother. 2021;70(4):935–44. https://doi.org/10.1007/s00262-020-02726-1.
Article
CAS
Google Scholar
Carow B, Hauling T, Qian X, Kramnik I, Nilsson M, Rottenberg ME. Spatial and temporal localization of immune transcripts defines hallmarks and diversity in the tuberculosis granuloma. Nat Commun. 2019;10(1):1823. https://doi.org/10.1038/s41467-019-09816-4.
Article
PubMed
PubMed Central
CAS
Google Scholar
Zhang N, Luo X, Huang J, Song H, Zhang X, Huang H, et al. The landscape of different molecular modules in an immune microenvironment during tuberculosis infection. Brief Bioinform. 2021. https://doi.org/10.1093/bib/bbab071.
Sakai S, Kauffman KD, Sallin MA, Sharpe AH, Young HA, Ganusov VV, et al. CD4 T Cell-derived IFN-γ plays a minimal role in control of pulmonary mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease. PLoS Pathog. 2016;12(5):e1005667. https://doi.org/10.1371/journal.ppat.1005667.
Article
PubMed
PubMed Central
CAS
Google Scholar
Lee JJX, Chan A, Tang T. Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin’s lymphoma. Acta Oncol. 2016;55(4):519–20. https://doi.org/10.3109/0284186X.2015.1125017.
Article
PubMed
Google Scholar
Fujita K, Terashima T, Mio T. Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis. J Thorac Oncol. 2016;11(12):2238–40. https://doi.org/10.1016/j.jtho.2016.07.006.
Article
PubMed
Google Scholar
Im Y, Lee J, Kim SJ, Koh W-J, Jhun BW, Lee S-H. Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors. Respir Med. 2020;161:105853. https://doi.org/10.1016/j.rmed.2019.105853.
Article
PubMed
Google Scholar
Chu Y-C, Fang K-C, Chen H-C, Yeh Y-C, Tseng C-E, Chou T-Y, et al. Pericardial tamponade caused by a hypersensitivity response to tuberculosis reactivation after anti-PD-1 treatment in a patient with advanced pulmonary adenocarcinoma. J Thorac Oncol. 2017;12(8):e111–e4. https://doi.org/10.1016/j.jtho.2017.03.012.
Article
PubMed
Google Scholar
Picchi H, Mateus C, Chouaid C, Besse B, Marabelle A, Michot JM, et al. Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment. Clin Microbiol Infect. 2018;24(3):216–8. https://doi.org/10.1016/j.cmi.2017.12.003.
Article
PubMed
CAS
Google Scholar